Walleye Capital LLC Fate Therapeutics Inc Transaction History

Walleye Capital LLC

$46.2 Billion
Q3 2024

A detailed history of Walleye Capital LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Walleye Capital LLC holds 67,609 shares of FATE stock, worth $150,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,609

Previous 18,600 263.49%

Holding current value

$150,091

Previous $61,000 286.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $152,908 - $272,980	49,009 Added 263.49%	67,609 $236,000
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $60,635 - $131,688	18,600 New	18,600 $61,000
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $103,547 - $247,258	-62,756 Reduced 61.53%	39,229 $146,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $578,865 - $1.44 Million	-286,567 Reduced 73.75%	101,985 $216,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $339,126 - $469,504	71,245 Added 22.45%	388,552 $1.85 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $1.29 Million - $3.37 Million	303,102 Added 2133.77%	317,307 $1.81 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $140,061 - $338,505	14,205 New	14,205 $143,000
Q2 2022 Aug 08, 2022	SELL	$17.78 - $42.39 $483,171 - $1.15 Million	-27,175 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $806,282 - $1.64 Million	27,175 New	27,175 $1.05 Million
Q4 2021 Mar 03, 2022	SELL	$47.84 - $64.34 $215,519 - $289,851	-4,505 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $267,011 - $431,263	4,505 New	4,505 $267,000
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $606,865 - $987,334	-8,410 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $320,336 - $848,989	8,410 New	8,410 $765,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account

Walleye Capital LLC Fate Therapeutics Inc Transaction History